1. In Vivo

Medtechs Should Not Play Dodgeball With Sales Force Effectiveness

 
• By Ashley Yeo

Adoption of sales force effectiveness remains suboptimal across the US medtech industry, which means that companies are missing out on significant annual revenue uplift. But things are changing, and it’s no longer an issue to be delegated: SFE has risen all the way to CEO level.

From a commercial standpoint, medtech has historically been dominated more by sales than by the marketing function. There has also been a strong clinical focus: the clinician stakeholder has traditionally been top of the priority list in all matters regarding the delivery of care – and by a long way.

But that has been changing over time, and the gap between the clinical stakeholder and the economic stakeholder has now...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Market Access

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.